Artikel
SSTR-2 as a potential tumor-specific marker for fluorescence guided meningioma surgery
Suche in Medline nach
Autoren
-
Arash Motekallemi
- Universitätsklinikum Münster, Klinik für Neurochirurgie, Münster, Deutschland
-
Bianca Dijkstra
- University Medical Center, Neurosurgery, Groningen, Niederlande
-
Hanne-Rinck (JR) Jeltema
- University Medical Center, Neurosurgery, Groningen, Niederlande
-
Wilfred F. A. den Dunnen
- University Medical Center, Pathology, Groningen, Niederlande
-
Frank A. E. Kruyt
- University Medical Center, Medical Oncology, Groningen, Niederlande
-
Rob J. M. Groen
- University Medical Center, Neurosurgery, Groningen, Niederlande
| Veröffentlicht: | 18. Juni 2018 |
|---|
Gliederung
Text
Objective: Meningiomas are the most frequently occurring primary brain tumors in adults. Surgical removal can only be curative with complete resection of the tumor. Several intraoperative techniques have been developed to improve surgical resection, including targeted intraoperative fluorescence guided imaging. To identify the most promising biomarker for intra-operative fluorescence guided meningioma surgery was the aim of this study.
Methods: 148 meningioma specimens representing all meningioma grades were analyzed using immunohistochemistry (IHC) on tissue microarrays (TMAs) to determine expression patterns of meningioma biomarkers epithelial membrane antigen (EMA), platelet derived growth factor β (PDGF-β), vascular endothelial growth factor α (VEGF-α), and somatostatin receptor type 2 (SSTR-2). Subsequently, the most promising biomarker was selected based on Target Selection Criteria (TASC). Marker expression was examined by IHC in 3D cell culture models generated from freshly resected tumor material.
Results: TMA-IHC showed strongest staining for SSTR-2. All cases were positive, with 30.4% moderate/diffuse and 51.4% strong/diffuse staining patterns. TASC analysis showed that SSTR-2 was the most promising target for fluorescence guided imaging, with a total score of 21 (out of 22). Eleven meningioma cultures, which could be maintained for several weeks, were generated. In three cultures, SSTR-2 expression was examined and confirmed in two cases.
Conclusion: SSTR-2 expression was highly sensitive and specific in all 148 meningiomas, regardless of the WHO grade. According to TASC analysis, SSTR-2 is the best target. After establishing in vitro meningioma models with a success rate of 50%, SSTR-2 cell membrane expression was confirmed in two of three meningioma cultures as well. Our findings indicate that SSTR-2 is a promising target for the further development of targeted fluorescence guided meningioma surgery.
